JBM (Healthcare) (HKG:2161) expects a year-over-year rise of at least 50% in attributable profit for the year ended March 31, a Monday Hong Kong bourse filing said.
The Chinese medicine distributor attributed the significantly higher profit mainly to strong sales from key brands, including Ho Chai Kung in the branded medicine and Po Chai Pills and Flying Eagle Woodlok Oil in the proprietary Chinese medicines segments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.